The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|April 27, 2018
A Case of Advanced Serous Ovarian Cancer
A Case of Advanced Serous Ovarian Cancer
Advertisement
Case: A 69-year-old Woman with Advanced Serous Ovarian Cancer
January 2017
- A 69-year-old Caucasian woman presented to the emergency department with shortness of breath
- PMH: mild HTN and DM, medically managed; morbid obesity
- PE: large volume ascites
- CT angiography (chest) showed large bilateral pulmonary effusions, no pulmonary thromboembolism
- Laboratory findings remarkable for CA 125, 525U/mL
- Thoracentesis (1500 cc); cytology showed high grade adenocarcinoma
- Paracentesis (4500 cc); cytology showed high grade adenocarcinoma
- Core biopsy of omentum; high grade serous carcinoma; p53 (+)/ PAX 8 (+) /WTI and CX 7 (+); BRCA1/2 wild-type
- The patient underwent debulking surgery with incomplete cytoreduction
- She was treated as part of a clinical trial with carboplatin/paclitaxel + bevacizumab followed by continuous bevacizumab maintenance
April 2018
- Fifteen months later, the patients complained of severe abdominal bloating and fatigue
- Imaging showed multifocal recurrence within the abdominal cavity
- CA 125, 322 U/mL
- ECOG 1
- She was started on carboplatin/docetaxel
- After 6 cycles of therapy she had a partial response to therapy with bulky residual disease
- She was initiated on rucaparib maintenance therapy, 600 mg BID
- Hb fell to 7.2 g/dl, managed with treatment interruption and then dose reduction to rucaparib 500 mg
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5